Format

Send to

Choose Destination
Pediatr Crit Care Med. 2018 Jun;19(6):e312-e320. doi: 10.1097/PCC.0000000000001525.

Hospital Variation in Intensive Care Resource Utilization and Mortality in Newly Diagnosed Pediatric Leukemia.

Fitzgerald JC1,2, Li Y2,3,4, Fisher BT2,5,6,7, Huang YS6, Miller TP3,7, Bagatell R3,7, Seif AE3,7, Aplenc R2,3,4,6,7, Thomas NJ8.

Author information

1
Department of Anesthesiology and Critical Care Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA.
2
Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
3
Divisions of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA.
4
Department of Biostatistics and Epidemiology, The Children's Hospital of Philadelphia, Philadelphia, PA.
5
Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, PA.
6
Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia Research Institute, The Children's Hospital of Philadelphia, Philadelphia, PA.
7
Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA.
8
Division of Pediatric Critical Care Medicine, Department of Pediatrics and Public Health Sciences, Penn State Hershey Milton S. Hershey Medical Center, Hershey, PA.

Abstract

OBJECTIVES:

To evaluate hospital-level variability in resource utilization and mortality in children with new leukemia who require ICU support, and identify factors associated with variation.

DESIGN:

Retrospective cohort study.

SETTING:

Children's hospitals contributing to the Pediatric Health Information Systems administrative database from 1999 to 2011.

PATIENTS:

Inpatients less than 25 years old with newly diagnosed acute lymphocytic leukemia or acute myeloid leukemia requiring ICU support (n = 1,754).

INTERVENTIONS, MEASUREMENTS, AND MAIN RESULTS:

Evaluated exposures included leukemia type, year of diagnosis, and hospital-wide proportion of patients with public insurance. The main outcome was hospital mortality. Wide variability existed in the ICU resources used across hospitals. Combined acute lymphocytic leukemia and acute myeloid leukemia mortality varied by hospital from 0% (95% CI, 0-14.8%) to 42.9% (95% CI, 17.7-71.1%). A mixed-effects model with a hospital-level random effect suggests significant variation across hospitals in mortality (p = 0.007). When including patient and hospital factors as fixed effects into the model, younger age, acute myeloid leukemia versus acute lymphocytic leukemia diagnosis, leukemia diagnosis prior to 2005, hospital-wide proportion of public insurance patients, and hospital-level proportion of leukemia patients receiving ICU care are significantly associated with mortality. The variation across hospitals remains significant with all patient factors included (p = 0.021) but is no longer significant after adjusting for the hospital-level factors proportion of public insurance and proportion receiving ICU care (p = 0.48).

CONCLUSIONS:

Wide hospital-level variability in ICU resource utilization and mortality exists in the care of children with leukemia requiring ICU support. Hospital payer mix is associated with some mortality variability. Additional study into how ICU support could be standardized through clinical practice guidelines, impact of payer mix on hospital resources allocation to the ICU, and subsequent impact on patient outcomes is warranted.

Comment in

PMID:
29528977
PMCID:
PMC5986594
DOI:
10.1097/PCC.0000000000001525
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center